I'm very happy with the Q2 results, and the information provided in the conference call. What I "got" from the con call is EXACTLY what I wanted to know!
#A - the financing/dilution... we were updated on the status, and I'm not concerned at all; we all understand this pretty well by now (or, at least anyone investing here or with any nano-cap stocks should clearly understand such things, and where RXMD is with financing right now). I wasn't expecting anything new here, nor did anyone that knows a thing or two.
Now the more important real info that goes to telling me the value and near-term potential upside for the stock:
#1 - explanation of S1 status: 1 question only from SEC in the latest (3rd) round of back-and-forth
#2 - confirmation of uplist plan still in place: still the plan, still within 2021
#3 - update on uplist plan status and catalyst for proceeding: new investment banker that they believe will get the job done
#4 - management declared the diversification plan and strategy to be THE plan, after successful 340B contract services BETA project that yielded SUBSTANTIAL revenue ($1.4M over 1st 6 months of 2021) and 127% growth y-o-y.
#5 - management committed to plan for Nationwide Rollout of 340B Contract Services business in Q1 of 2022
#6 - management has made it a serious goal to be a $1B diversified healthcare technology services business within 5 years
Great stuff, glad to be here!
News 
Market Data 
Discover 
